Bristol-Myers Squibb (BMY) Q4 2025: Growth Portfolio Hits 60% of Revenue as Legacy Step-Down Looms
Bristol-Myers Squibb’s growth portfolio now accounts for nearly 60% of revenue, offsetting a $4 billion legacy decline and redefining its business mix. With a packed pipeline and disciplined cost controls, BMY faces a pivotal 2026 as loss of exclusivity accelerates for key brands and pivotal data readouts approach. Investors must weigh near-term growth against the looming impact of patent cliffs and evolving competitive dynamics.
Summary
- Growth Portfolio Overtakes Legacy: Newer products now drive the majority of revenue, signaling a structural shift in BMY’s business mix.
- Pipeline Readouts to Define 2026: Over ten pivotal trials and six registrational data sets set the stage for portfolio transformation.
- Patent Expiries Pressure 2027 Outlook: Loss of exclusivity on major brands, especially in Europe, signals a sharp legacy revenue step-down ahead.
Business Overview
Bristol-Myers Squibb (BMY) is a global biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines. Revenue is driven by a mix of oncology, cardiovascular, immunology, and neuroscience therapies. The business is split between a legacy portfolio (mature, high-volume drugs facing patent expiry) and a growth portfolio (recently launched or expanding brands such as Reblozil, Breyanzi, Camzyos, Opdualag, and CoBEMFI). BMY also invests heavily in R&D to advance its pipeline and maintain long-term growth.
Performance Analysis
BMY’s Q4 2025 results highlight a decisive pivot toward its growth portfolio, which delivered 15% revenue growth and now represents close to 60% of total sales. Key brands, including Reblozil, Breyanzi, Camzyos, and Opdualag, each contributed over $1 billion in annual sales, with Reblozil surpassing $2 billion. This surge nearly offset a $4 billion decline in the legacy portfolio, demonstrating management’s ability to navigate patent expiries with new product launches.
Cell therapy and cardiovascular franchises also posted robust gains. Breyanzi’s 47% growth and Camzyos’ 57% increase underscore the company’s execution in high-value specialty markets. Eloquis, despite pricing headwinds and an impending patent cliff, grew 6% on continued demand and share gains. However, gross margin declined 210 basis points to 71.9% due to product mix shifts—an early sign of revenue transitioning from high-margin legacy drugs to newer, potentially lower-margin therapies.
- Growth Portfolio Expansion: Revenue from new launches is now the primary engine, with legacy erosion nearly offset.
- Margin Compression from Mix Shift: Declining gross margin reflects the transition to newer products and pricing resets.
- Cost Controls Deliver Flexibility: $1 billion in productivity savings achieved in 2025, enabling reinvestment in launches and pipeline.
Cash flow and balance sheet strength remain solid, supporting both continued pipeline investment and disciplined capital returns. Yet, the anticipated $1.5 to $2 billion Eloquis step-down in 2027 foreshadows future top-line pressure as exclusivity wanes.
Executive Commentary
"Our growth portfolio grew 15% year-over-year in Q4 and 17% for the full year. In terms of building out breadth with newer products, Opdualag, Breyanzi, and Camzyos each contributed over $1 billion in sales for the full year, while Reblozil delivered over $2 billion. These are differentiated, durable products early in their life cycles with meaningful runway ahead that further strengthen the foundation for long-term growth."
Chris Boerner, Board Chair & Chief Executive Officer
"We made significant progress during 2025 against our $2 billion strategic productivity initiative. As of the end of the fourth quarter, we delivered on a target of approximately $1 billion in savings in 2025, and are on track to realize the remaining billion dollars over 2026 and 2027."
David Elkins, Chief Financial Officer
Strategic Positioning
1. Growth Portfolio as Core Value Driver
BMY’s growth portfolio is now structurally central, with new launches accounting for nearly 60% of revenue. Management’s focus is on maximizing uptake, broadening indications, and accelerating international launches—especially for Opdualag, Breyanzi, Camzyos, and CoBEMFI.
2. Pipeline-Driven Transformation
The 2026 pipeline is data-rich, with over ten pivotal readouts and six registrational trials across hematology, oncology, and specialty indications. Milvexian, Admilpirant, ibertamide, and Arlo cell therapies are positioned as potential near-term blockbusters, with management highlighting confidence in both efficacy and commercial opportunity.
3. Cost Discipline and Reinvestment
Ongoing cost savings initiatives have delivered $1 billion, with another $1 billion targeted through 2027. This discipline enables BMY to reinvest in high-growth launches, next-generation R&D, and business development without sacrificing margin stability in the near term.
4. Navigating Patent Expiry and LOE
Loss of exclusivity (LOE) remains a defining headwind, with Eloquis and other legacy products facing generic erosion, especially as EU patents expire late 2026. Management is transparent about a $1.5 to $2 billion Eloquis step-down in 2027, emphasizing the urgency of pipeline execution.
5. Business Development and Portfolio Depth
BMY remains opportunistic but disciplined in business development, targeting bolt-on deals in existing therapeutic areas rather than chasing scale for its own sake. Management stresses a focus on science-driven, high-return opportunities that complement internal pipeline strengths.
Key Considerations
BMY’s quarter underscores a company in strategic transition, balancing robust growth from new launches with the realities of legacy revenue decline and the patent cliff. The ability to execute on multiple fronts—commercial, operational, and clinical—will determine if BMY can sustain its growth narrative into the next decade.
Key Considerations:
- Growth Portfolio Momentum: Execution on launches and indication expansions is critical to offsetting legacy declines.
- Pipeline Catalysts: Over ten pivotal readouts in 2026 could reshape the revenue base and investor perception of durability.
- Cost Structure Flexibility: Realized and targeted savings provide reinvestment capacity, but future margin pressure is likely as mix shifts further.
- Patent Cliff Timing: Eloquis and other legacy drugs face rapid revenue compression post-2026, especially in Europe.
- BD Discipline: Management’s selective approach to M&A and partnerships seeks to avoid overpaying for growth while deepening core franchises.
Risks
Patent expiries and generic entry, particularly for Eloquis, pose a material risk to revenue and margin beginning late 2026 and accelerating in 2027. Pipeline execution risk is elevated, with multiple pivotal data readouts required to support future growth. Competitive dynamics in key markets—including immunology, oncology, and neuroscience—could limit upside from new launches if differentiation is not demonstrated. Regulatory and pricing pressures, especially in the U.S. and EU, remain persistent headwinds.
Forward Outlook
For Q1 2026, BMY guided to:
- Seasonal sequential revenue decrease due to inventory destocking
- Eloquis revenue expected to be higher in the second half than the first half of 2026
For full-year 2026, management guided:
- Total revenue of $46 to $47.5 billion
- Gross margin of 69% to 70%
- Operating expenses of ~$16.3 billion, down from 2025
- Non-GAAP EPS of $6.05 to $6.35
Management highlighted:
- Continued strong growth from the growth portfolio
- Legacy portfolio revenue decline of 12% to 16% due to LOE
- Major pipeline data readouts as critical near-term catalysts
Takeaways
- Portfolio Transition Accelerates: The growth portfolio’s rise to 60% of revenue signals a structural business reset, but legacy headwinds are not yet behind BMY.
- Pipeline Execution is Non-Negotiable: With over ten pivotal data readouts in 2026, the next twelve months will define BMY’s long-term growth trajectory and ability to replace legacy revenue.
- Patent Cliff Demands Urgency: Investors should closely watch the cadence of launches and data, as the 2027 Eloquis step-down and other LOE events will test BMY’s new foundation.
Conclusion
Bristol-Myers Squibb enters 2026 with commercial momentum and a deep pipeline, but faces a narrowing window to convert innovation into sustainable growth before legacy revenues decline sharply. Disciplined cost management and execution on pivotal trials are now the critical levers for valuation and future competitiveness.
Industry Read-Through
BMY’s results reflect a broader biopharma industry shift—from legacy blockbusters to diversified growth portfolios and pipeline-driven value. The company’s transparency on patent cliffs and cost discipline sets a template for peers facing similar transitions. Pipeline productivity and launch execution are now the defining metrics for sector leaders, with investors increasingly focused on the ability to offset LOE through innovation and operational agility. Competitive intensity in oncology, immunology, and neuroscience will likely increase as more companies chase smaller, specialized indications and seek to demonstrate differentiation beyond first-in-class status.